ABSTRACT
respect, SP-D is colocalized with IgA of the adaptive immune system (J.M. and U.H., unpublished work). Like the other collectins, SP-D binds to repeating carbohydrate moieties on pathogenic microorganisms and is considered to be a patternrecognition molecule of the innate immune system (3). This binding enhances phagocytosis and killing of microorganisms by neutrophils and alveolar macrophages (4, 5) . The binding also results in aggregation of the microorganisms and hindrance of infection. SP-D also binds directly to alveolar macrophages in the absence of microbial ligands, thereby mediating the generation of oxygen radicals (6) , and acts as a potent chemotactic agent for phagocytes (7, 8) . SP-D has been localized in endocytic vesicles and in lysosomal granules of alveolar macrophages (9, 10) , suggesting that it is involved in receptor-mediated uptake by these cells. SP-D has also been shown to inhibit T lymphocyte proliferation and IL-2 production (11) .
SP-D interacts with surfactant-associated phospholipids in vitro (12, 13) , and mice made SP-D-deficient by gene targeting showed a progressive accumulation of surfactant lipids in the alveolar space. The SP-D null mice also showed an accumulation of alveolar macrophages, many of which were multinucleated and foamy in appearance. The alveolar type II cells in these animals were hyperplastic and contained giant lamellar bodies. These findings suggest that SP-D also plays a role in surfactant homeostasis (14, 15) .
No receptor responsible for the effector mechanisms of SP-D has yet been characterized. A molecule, designated gp-340, which copurifies with SP-D on carbohydrate affinity columns, has been isolated and shown to bind SP-D in a calcium-dependent manner (16) . It has also been established that the binding of SP-D to gp-340 is a protein-protein interaction rather than a lectin-carbohydrate interaction. Recently, it was shown that gp-340 also may bind to SP-A (17) . Protein sequencing showed that gp-340 was a member of the scavenger receptor cysteine-rich (SRCR) superfamily (16) .
The gp-340 molecules exist both in a soluble form and in a form associated with the alveolar macrophage membrane. In the present paper, we describe the primary structure of gp-340 and its tissue distribution. It seems probable that the molecular interaction between SP-D and gp-340 plays an important role in innate immunity on mucosal surfaces.
MATERIALS AND METHODS
cDNA Cloning and Sequencing. A pool of 29-base oligonucleotide ''guessmers'' with a redundancy of 384 was synthesized
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in accordance with the codon usage of the underlined amino acids of the gp-340 peptide SWGTV(C)DDYWDTNDANV (16 RNA from human trachea was transcribed into cDNA with the Marathon cDNA Kit (both purchased from CLONTECH) and diluted 1:250. A 5-l portion of the dilution was used as template in a 50-l PCR that further contained 5 l of P3 buffer (Expand Long Template PCR System, Boehringer Mannheim), 400 M each dNTP, 0.75 l of a 9:1 (Taq:Pfu) polymerase mix (Taq: 5 units͞l, Perkin-Elmer; Pfu: 2 units͞l, Stratagene), and 15 pmol each primer (dmbt1.1f, 5Ј-ATACCACCCTAGAGGACACACC-3Ј, and dmbt1.2r, 5Ј-GCAGTTCACCAAAATTCCTT-3Ј). The PCR was performed as follows: an initial denaturation for 2 min at 94°C; 30 cycles of 20 s at 92°C, 30 s at 59°C, and 10 min at 68°C; and a final extension for 10 min at 72°C. The PCR products were cloned with the TOPO XL PCR Cloning Kit (Invitrogen) according to the instructions of the supplier, and insert sizes were determined by NotI-HindIII digestion and subsequent agarose gel electrophoresis. A DMBT1 clone with an insert of about 8 kilobases (kb; DMBT1͞8-kb.2) was selected for sequencing by using the nested-deletion method (Nested Deletion Kit, Amersham Pharmacia). Sequencing was carried out by using dye terminator chemistry (Amersham Pharmacia) and automated DNA sequencers (Applied Biosystems model 373A͞377). The cDNA clone contained frameshift mutations in codons 100 and 1,751 that were corrected by comparison with the genomic sequence of the gene (18) .
Immunohistochemistry. Normal human tissues and cell pellets from bronchoalveolar lavage fluid were fixed in 4% (vol͞vol) formalin in PBS for 24 h and then conventionally dehydrated and embedded in paraffin. A streptavidin-biotin immunoperoxidase staining technique was used on the paraffin-embedded sections, which were treated in a microwave oven to unmask epitopes (19) . A monoclonal (Hyb 213-1) or polyclonal antibody against gp-340 and a monoclonal (Hyb 245-1) antibody against SP-D were used, followed by biotinlabeled goat anti-mouse Ig (E433, Dako) or biotin-labeled goat anti-rabbit Ig (E432, Dako). After incubation with streptavidin conjugated to horse-radish peroxidase (P397, Dako), the sections were incubated with carbazole buffer [0.04% 3-amino-9-ethylcarbazole (Sigma, A-5754)͞0.015% H 2 O 2 ͞50 mM sodium acetate buffer, pH 5.0], counterstained with Mayer's hematoxylin, and mounted in Aquatex (Merck). The specificities of the antibodies used for immunohistochemistry are described in ref. 16 . Controls were performed by replacing the primary monoclonal antibody with an unrelated monoclonal antibody of the same subclass as the gp-340 antibody or by preabsorbing the primary polyclonal antibody with highly purified gp-340.
Reverse Transcriptase-PCR (RT-PCR). Total RNA (2 g) isolated from various human tissues (CLONTECH) was used for first-strand synthesis by using the antisense primer DMBT1c, 5Ј-GAGAGGGGA ACTGCGGTAG-3Ј. This primer corresponds to nucleotides 6,316-6,334 of gp-340 cDNA. The RNA was incubated in a volume of 20 l with 1 unit͞l M-MuLV reverse transcriptase (Stratagene) for 1 h at 37°C. One-fourth of the resulting single-stranded cDNA was subjected to 40 cycles of PCR amplification in a volume of 30 l (denaturing at 94°C for 30 s, annealing at 62°C for 1 min, extension at 72°C for 2 min, and a final extension at 72°C for Proc. Natl. Acad. Sci. USA 96 (1999) 10795 gp-340 primers spanning the region between the SRCR 13 and the CUB 2 (a domain first found in complement component C1r͞C1s; Uegf, a sea urchin epidermal growth factorcontaining protein; and Bmp1, bone morphogenetic protein-1) domains. The sense primer DMBT sca9 (5Ј-ATTCATCCTAT-GGTCTA-3Ј) corresponded to nucleotides 5,772-5,788 of gp-340 cDNA, and the antisense primer was the same as the one used for cDNA synthesis. As a control, a single-stranded cDNA copy of ␤-actin was synthesized and amplified by PCR under the same conditions as gp-340, except that the PCR annealing temperature was 58°C and the primers used were 5ЈAKTI, 5Ј-GGCATGGCTTTATTTGTTTT-3Ј (sense), and 3ЈATKI, 5Ј GTAAGCCCTGGCTGCCTC-3Ј (antisense). The entire volume of each reaction mixture was subjected to electrophoresis on a 1.5% (wt͞vol) agarose gel, blotted onto a nylon membrane, and hybridized with the respective PCR products labeled with [␣- 
RESULTS AND DISCUSSION
Oligonucleotides based on the amino acid sequence of a gp-340 peptide were used to retrieve a single clone (gp-clone 1A) from a lung cDNA library. The translated sequence of this clone was found to include the sequence used to design the oligonucleotides. With this clone as template, a PCR product was generated and used for further screening of lung cDNA libraries, and a PCR product located at the 3Ј end of the zona pellucida (ZP) domain was also used for screening. An additional eight cDNA clones were obtained: gp-clones 7, 8, 3.1, 3.2, 5.1, 7.1, 8.1, and 8.2. The last six included the 3Ј end of the cDNA, whereas gp clones 7 and 8 were found to be internal, overlapping cDNA clones. Additional cDNA clones were found as expressed sequence tags. The sequences of these clones revealed a high homology but not identity with the 6-kb form of DMBT1, a gene recently identified as a candidate tumor suppressor gene for tumors of the central nervous system (20) . Northern blotting showed that DMBT1 is expressed with transcripts of 6.0, 7.5, and 8.0 kb in fetal lung and with one transcript of 8.0 kb in adult lung. Long-range PCR with primers from the 5Ј and 3Ј ends of DMBT1 gave an 8.0-kb product that included the sequence data obtained from the cDNA cloning and allowed the assembly of a 7,687-bp cDNA starting with a 5Ј untranslated region of 107 bp, followed by an ORF of 7,239 bp and a 3Ј untranslated region of 341 bp ending with a poly(A) tail. The nucleotide sequence revealed that gp-340 and the 6.0-kb form of DMBT1 represent alternatively spliced forms of the same gene (20) . The combined nucleotide sequences of gp-clones 7, 8, and DMBT1͞6-kb and DMBT1͞ 8-kb.2 have been deposited at the European Molecular Biology Laboratory nucleotide sequence database (accession nos. AF159456 and AJ243212).
The domain organization of gp-340 is shown in Fig. 1 , together with details of the cDNA clones that were characterized and the long-range PCR products. The sequence shown is the assembled sequence of DMBT1͞6-kb, gp-clone 7, and gp-clone 8. The ORF encodes a polypeptide chain of 2,413 amino acids, including a possible signal peptide of 25 residues (Fig. 2) . gp-340 is a glycoprotein with an apparent molecular mass of 340 kDa as determined by SDS͞PAGE. When the signal peptide is omitted, the calculated molecular mass of the polypeptide chain is 258,069 kDa. The isoelectric point is calculated as 5.18, and the molar extinction coefficient at 280 nm is calculated as 605,350 M Ϫ1 ⅐cm
Ϫ1
(corresponding to an absorbance at 280 nm of 1.0 for a solution of the unglycosylated protein chain at 0.43 mg͞ml). The molecular mass of gp-340 purified from human bronchoalveolar lavage fluid is reduced to 300 kDa after deglycosylation. This reduction is consistent with the presence of the 14 putative sites for N-linked glycosylation found in the deduced amino acid sequence (Fig. 2) . The domain organization of gp-340 features 13 SRCR domains (21) separated by SIDs, except for SRCR domains 4 and 5, which are contiguous. The SRCR domains are followed by a short Thr-rich region, a CUB domain (22, 23) , a 14th SRCR domain, a Ser-Thr-Pro-rich region, a second CUB domain, and a ZP domain. Compared with the gp-340 sequence, the 6-kb form of DMBT1 lacks the C-terminal half of SIDs 3, 5, and 6, the N-terminal part of SID 7, and SRCR domains 4, 5, 6, and 7 (Fig. 3) . DMBT1 also lacks the equivalent of one SID and one SRCR domain between SIDs 9 and 11 of gp-340. However, because SIDs 9 and 10 are 100% identical at the nucleotide level, as are SRCR domains 10 and 11, it is impossible to deduce exactly where the alternative splicing is located. Identities and similarities between the different domains are shown in the sequence alignments presented in Fig. 3 . A remarkable level of similarity is found among the first 13 SRCR domains (88-100% identity), and the 14th SRCR domain shows 65% identity with the other SRCR domains (Fig. 3A) . All the SRCR domains have eight conserved cysteine residues and belong to group B of the SRCR family (21) . The SID domains are Ser-Thr-Pro-rich (60%) and can be separated in two groups showing high within-group similarity (Fig. 3B) . The two CUB domains are 52% identical (Fig. 3C) . The ZP domain is followed by a stretch of 28 residues that show a high degree of similarity to equivalent regions of CRP-ductin (24) and Ebnerin (25) (Fig. 3D) . Two cDNA variants of CRP-ductin have been characterized. CRP-ductin-␣ is an alternative spliced form of CRP ductin-␤ that lacks the Tm region and the short cytoplasmic tail (24) . All the isolated gp-340͞DMBT1 cDNA clones have a stop codon after residue 2,413, and this stop codon seems to be placed similarly to that in CRP-ductin-␤ (Fig. 3D) . The intron͞exon structure of the gp-340͞DMBT1 gene has been characterized (18) , and an exon encoding a putative Tm region of gp-340͞DMBT1 was identified approximately 1.8 kb from the stop codon. Alignment of this exon with the same region of CRP-ductin and Ebnerin showed that it starts exactly where CRP-ductin-␣ continues the sequence of CRP-ductin-␤ (Fig. 3D) . Thus far, no cDNA clones coding for the Tm region of gp-340͞DMBT1 have been obtained.
Northern blot analysis of DMBT1 revealed an 8-kb transcript in fetal and adult lung, and additional bands of 6.0 and 7.5 were visible in fetal lung and adult small intestine (20) . Western blotting of bronchoalveolar lavage fluid showed two closely spaced bands corresponding to molecular masses of approximately 340 kDa, and one band corresponded to 200 kDa (16) . The top band could represent the translated form of the full-length 8-kb transcript, whereas the lower bands could be alternatively spliced forms of the DMBT1 gene. By performing RT-PCR on 19 different tissues, it was shown that the main sites of synthesis of gp-340͞DMBT1 are lung, trachea, salivary gland, small intestine, and stomach (Fig. 4) . Minor sites of synthesis were brain, testis, uterus, prostate, pancreas, and mammary gland, and little or no synthesis was found in heart, placenta, adrenal gland, spleen, skeletal muscle, thymus, liver, or kidney (Fig. 4) .
Immunohistochemistry revealed strong immunostaining for gp-340 in the alveolar macrophages of the lung (Fig. 5 a-g ). In some macrophages, gp-340 was found to be uniformly distributed on the membrane. Other macrophages showed a focal membrane staining (capping), and yet other macrophages were strongly stained in the phagosome͞phagolysosome compartments. In some macrophages, SP-D and gp-340 were found colocalized in the same cell compartment (Fig. 5 g-h) . This distribution of gp-340 in the macrophages is compatible with the concept that gp-340 is an opsonin receptor for SP-D. Immunoreactive gp-340 was also found in the epithelial cells of the small intestine (Fig. 5k) and in the ducts of salivary glands (Fig. 5i) . In the pancreas, gp-340 was located in certain cells of the islets of Langerhans (Fig. 5j) . The main site of synthesis of CRP-ductin is the small intestine, but CRP-ductin is also found in the exocrine pancreatic and hepatic ducts. By using RT-PCR, we have found that CRP-ductin also is expressed in the lung (J. Madsen and U.H., unpublished work). Ebnerin is found specifically in the secretory duct epithelial cells of the lingual salivary glands of the rat and does not seem to be expressed in either lung or large intestine. Pema-SREG was cloned from a gut cDNA library from the sea lamprey Petormyzon marinus (Fig. 3E; ref. 26 ). This molecule features two SRCR domains that are separated by four EGF domains and a ZP domain followed by a Tm region and a cytoplasmatic tail. The biological function of CRP-ductin and Ebnerin are unknown, but the domain organization of these two molecules and gp-340 indicates that they are homologous proteins in human, mouse, and rat. However, functional studies showing that murine SP-D binds to CRP-ductin are needed to determine whether this homology is the case.
Previously, DMBT1 has been proposed as a candidate tumor suppressor gene implicated in the carcinogenesis of brain tumors (20) . This conclusion was reached based on the findings of homozygous deletions and lack of expression in medulloblastomas and glioblastoma multiforms. Similar results were obtained for a substantial fraction of gastrointestinal and lung tumors (27, 28) . The finding that gp-340 is an alternative spliced form of the DMBT1 gene raises the possibility that DMBT1 may not be a classical tumor suppressor gene but rather play a role in the interaction of tumor cells and the immune system. Recently, MBL has been shown to recognize and bind specifically to oligosaccharide ligands expressed on the surfaces of a human colorectal carcinoma (29) . Recombinant vaccinia virus carrying the human MBL gene was shown to possess a potent growth-inhibiting activity against human colorectal carcinoma cells transplanted in nude mice when administered by intratumoral or subcutaneous injection; a significant prolongation of life span of tumor-bearing mice resulted from the treatment. This effect seems to be a consequence of local production of MBL, and it was anticipated that the killing of the tumor cell was mediated by complement activation and lysis of the tumor cell. Surprisingly, a mutant form of MBL, which had essentially no complement-activating activity, was nearly as active as wildtype MBL, and the results therefore indicate that MBL has a cytotoxic activity on its own (29) .
Recently, gp-340 also has been shown to bind SP-A in a calcium-dependent manner that is independent of the latter's lectin activity (17) , but gp-340 neither affected the binding of SP-A to alveolar macrophages nor inhibited the ability of SP-A to stimulate macrophage chemotaxis. It was shown that gp-340 alone stimulates the random migration of alveolar macrophages in a manner independent of SP-A-stimulated chemotaxis.
Taken together, the present findings indicate that gp-340 may be an opsonin receptor for SP-A and SP-D located in tissue macrophages throughout the body and in epithelial cells lining the gastrointestinal tract. gp-340͞DMBT1 is expressed in several different molecular forms, and the lung collectins bind to at least one of these forms. We suggest that this interaction may be involved in clearance of microorganisms; in addition, because SP-D has a carbohydrate-binding profile similar to that of MBL, we speculate that SP-D together with gp-340 may be in involved in the immune surveillance of cancer.
